NIH R01 · 2024
Enhancing Treg Therapeutic Efficacy in GVHD
Abstract: This renewal continues our optimization of regulatory T cell (Treg) therapy for creating transplant tolerance to prevent graft-vs-host disease (GVHD). Our first-in-human phase I CD4 thymic Treg (tTreg) and CD4 inducible Treg (iTreg) trials that showed reduction but not elimination of GVHD. Importantly, relapse rates were not improved and decreasing GVHD but not relapse is an insufficient outcome. In this renewal, we will build on our exciting finding that Tregs can acquire super-suppressor function and by incorporating an anti-CD19 scFv CAR (CAR19) increase their potency of killing. In other studies, we developed highly suppressive CAR19 CD8 iTregs that have an intrinsic killing…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.